Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Sarcoma 3Thoracic 1Dermatologic 1

Conditions

Melanoma 10Lymphoma, T-Cell, Cutaneous 5Mycosis Fungoides 4Sezary Syndrome 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, T-Cell 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Radiosurgery 22Ipilimumab 17Nivolumab 16pembrolizumab 11Temozolomide 9encorafenib 8dabrafenib 8binimetinib 8Magnetic Resonance Spectroscopy 6trametinib 5Bevacizumab 5CTLA-4 Antigen 4cobimetinib 3Thalidomide 3Radiotherapy 3Paclitaxel 3entrectinib 2cediranib 2Vemurafenib 2Spermine Synthase 2Specimen Handling 2Radiation 2Pemetrexed 2Opdualag 2Drug Therapy 2Carboplatin 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 214-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 2130-nm albumin-bound paclitaxel 2relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Disulfides × Dermatologic × Clear all
NCT03175432 2026-04-15

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡